Article Sidebar

Submitted
Apr 17, 2021
Published
Apr 17, 2021
Download
PDF
Statistic
Read Counter : 40 Download : 23

Main Article Content

Abstract

Objective:To compare the therapeutic benefit of monotherapy and multiple therapy by assessing clinical outcome (BP measurement), To address and document the various adverse effects observed during monotherapy and multiple therapies for hypertensive patients, To compare the cost of both therapies during the treatment.


Material and Methods:Two groups were included during the period of study, monotherapy and second group who received multiple therapy( dual therapy, triple therapy, quadruple therapy) ; Comparative study was done by measuring the outcome clinically by observing change in the BP. safety of the treatment regimen was assessed by observing the ADRs and cost comparison was carried out between the groups. ANOVA test was applied to check the statistical significance of the above mentioned parameters.


Results: Out of total 200 patients, most of the patients (127) were females and the remaining (73) were males. Among 200 patients enrolled, 152 patients had hypertension along with other co morbidities and diabetes was the most common co morbid condition which was present in 126 patients. Most of patients were treated with monotherapy (96) which was followed by dual therapy (76). In monotherapy T.Furosemide reduced SBP by 50 mmHg and T.Nifedipine and T.Metoprolol Reduced DBP by 20 mmHg, whereas in dual therapy Inj. furosemide, T.Metoprolol decreased mean SBP by 60 mmHg and DBP by 40 mmHg respectively.  Results showed that, triple drug therapy was most effective in reducing mean systolic (41.8-24%) and mean diastolic blood pressure (16.8-16.6%) and reduction of SBP by triple therapy was higher compared to other therapies.


Conclusion: Combination therapy reduces both mean systolic and diastolic blood pressure compared to monotherapy. Triple drug therapy is more effective compared to dual and quadruple therapy. Pedal edema due to amlodipine is the most common ADR in both mono and multiple therapies. Combination therapy is more expensive than monotherapy, however triple therapy was most expensive compared to others.

Keywords

Hypertension Blood pressure Antihypertensive Monotherapy Multiple therapies

Article Details

How to Cite
Sara Azad, Kobra Najafzadeh, Dr.Shobharani R.H, Dr.R.Shankarprasad, & Mahvash Iram. (2021). A study on comparison of monotherapy versus combination therapy for hypertensive patients at tertiary care hospital. International Journal of Research in Pharmacology & Pharmacotherapeutics, 4(1), 59-68. https://doi.org/10.61096/ijrpp.v4.iss1.2015.59-68
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1] DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG,Posey LM, editors. Pharmacotherapy: a patho physiologic approach [Internet]. 7th ed. NewYork: Mc Graw Hill; 2008[ cited 2010 Jun 15].
  2. [2] Satoskar et al, Pharmacology and Phamacotherapeutics, Revised 18th edition, 2003 : 396-26
  3. [3] P.Kearney,et at Global burden of hypertension: analysis of worldwide data The Lancet, Vol 365, Issue 9455, 217-223.
  4. [4] Harrison’s principles of internal medicine, 2001 ;15th edition; vol1 ; 1414-29.
  5. [5] Davidson’s principles and practice of medicine, 18th edition 1999 ; 216-22.
  6. [6] Gaziano T, Reddy KS, Paccaud F, Horton S, Chaturvedi V. Cardiovascular disease. In: Jamison DT, Mosley WH, editors. Disease Control Priorities in the Developing World. Oxford: Oxford University Press; 2006. pp. 645–62.
  7. [7] The World Health Report 2002: Reducing Risk, Promoting Healthy Life. Geneva, Switzerland: World Health Organization; 2002. World Health Organization.
  8. [8] O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): A case-control study. Lancet.2010;376:112–23.
  9. [9] Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet.2004;364:937–52.
  10. [10] Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet. 1997;349:1498–504.
  11. [11] Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet. 2005;365:217–23.
  12. [12] Gupta R, Gupta VP. Hypertension epidemiology in India: Lessons from Jaipur Heart Watch. Curr Sci.2009;97:349–55.
  13. [13] Gupta R, Sharma AK, Gupta VP, Bhatnagar S, Rastogi S, Deedwania PC. Increased variance in blood pressure distribution and changing hypertension prevalence in an urban Indian population. J Hum Hypertens.2003;17:535–40.
  14. [14] Reddy KS, Prabhakaran D, Chaturvedi V, Jeemon P, Thankappan KR, Ramakrishnan L, et al. Methods for establishing a surveillance system for cardiovascular diseases in Indian industrial populations. Bull World Health Organ. 2006;84:461–9.
  15. [15] Hypertension Study Group. Prevalence, awareness, treatment and control of hypertension among the elderly in Bangladesh and India: A multicentre study. Bull World Health Organ. 2001;79:490–500.
  16. [16] Gupta R. Trends in hypertension epidemiology in India. J Hum Hypertens. 2004;18:73–8.
  17. [17] Malhotra P, Kumari S, Kumar R, Jain S, Sharma BK. Prevalence and determinants of hypertension in an un-industrialised rural population of North India. J Hum Hypertens. 1999;13:467–72.
  18. [18] Gupta R, Gupta VP, Ahluwalia NS. Educational status, coronary heart disease, and coronary risk factor prevalence in a rural population of India. BMJ. 1994;309:1332–6.
  19. [19] Todkar SS, Gujarathi VV, Tapare VS. Period prevalence and sociodemographic factors of hypertension in rural Maharashtra: A cross-sectional study. Indian J Community Med. 2009;34:183–7.
  20. [20] K R Thankappan et al Community Based Detection and Monitoring Of Hypertension in Kumarakom Panchayat, Kottayam: Epedemiologic aspects of hypertension in world: WHO (TRS) No 862: 1996 on Hypertension.
  21. [21] Williams B, Poulter NR, Brown MJ, et al. Guidelines for the management of hypertension: report of the fourth working party of the British Hypertension Society, 2004 – BHSIV. J Hum Hypertens. 2004;18:139-185.
  22. [22] Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427-1434.
  23. [23] David A, Nora A ,Joseph Y , Robert D Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety.2009;26(11):1012-1023
  24. [24] Ruzicka M, Leenen FH. Combination therapy as first line treatment of arterial hypertension. 2002;18(12):1317-1327
  25. [25] Michael B, Edgar A. Optimizing combination therapy in the management of hypertension: the role of the aliskiren,amlodipine, and hydrochlorothiazide fixed combination. 2010;23(1):38–45
  26. [26] Heinrich H.combination versus monotherapy as initial treatment in hypertension. 2003 ;28(8)725-732
  27. [27] Panjabi S, Michael L ,Bancroft T .treatment adherence ,clinical outcomes,and economics of triple-drug therapy in hypertensive patient .The health advance journal .2013; 7(1): 46-60
  28. [28] Qiuping Gu. Antihypertensive medication use among US adults with hypertension. Circulation 2006;113;213-221.